Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide interaction study with edoxaban and morphine in prostate cancer
NL-OMON58959Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enzalutamide, edoxaban and morphine in prostate cancer (PCa) (4 arms), sponsored by Radboud University Medical Center. Primary endpoints: Change in edoxaban exposure, Change in M4 exposure and 2 more. Started Feb 2023; status: completed.
02
Drugs
enzalutamideedoxabanmorphine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON58959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58959.